The effects of depression, stress, and somatization on clinical prognosis and treatment in patients suspicious of benign prostatic hyperplasia

Main Article Content

Muhammad Sarim Khan , Muhammad Yawar Mushtaq, Usama Shoukat, Nauman Ahmed

Keywords

Depression, stress, somatoform disorder, lower urinary tract signs prostatic hyperplasia.

Abstract

Aim: It was the first research to study how depression, stress, and somatoform disorder affect therapy reply for lower urinary tract symptoms (LUTS), suspicious of benign prostatic hyperplasia (BPH). Method: Respondent Health Questionnaire-9,7- item Sweeping Nervousness Syndrome Scale, and PHQ 17 are being used to assess LUTS/BPH individuals. The main result was just the responder’s rate, which was defined as total IPSS score (6) at the conclusion of therapy. Results: The intensity of LUTS/BPH was considerably greater in people experiencing sadness (p value = 0.025; storage sub-sign (p value = 0.023) or else somatization (p value = 0.026) than in these deprived of, although standard of living remained higher for cases experiencing anxiousness (p value = 0.039) than that 
of other deprived of. Nervous participants had a substantially larger number of non than those who were not (odds ratios [OR], 4.295, P = 0.023), whereas somatic respondents had the tendency to have greater non-responders (OR, 4.553, p value = 0.068). Our preliminary findings imply that sadness, anxiety, and somatic complaints might have had an impact on treatment manifestations of LUTS/BPH. Furthermore, apprehensive individuals with LUTS/BPH exhibited a worse response to therapy. Conclusion: Despite its drawbacks, the current study shows that doctors may also need to conduct a detailed examination of psychotic features in order to successfully manage individuals suffering LUTS/BPH. 

Abstract 27 | PDF Downloads 5

References

1. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain
interaction. Gastroenterology. 2019; 150(6): 1257- 1261.
2. Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV
functional bowel disorders among adults in the United States, Canada, and the United
Kingdom. Gastroenterology. 2020; 158(5): 1262- 1273.e1263.
3. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features
and Rome IV. Gastroenterology. 2019; 150(6): 1262- 1279.
4. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2019; 150(6): 1393- 1407.
5. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel
disorders. Gastroenterology. 2019; 130(5): 1480- 1491.